AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets
Partnership combines AbTherx’s proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics’ deep expertise in GPCR